Victor Hontanon
La Paz, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Immune Factors Linked to Long-Term HCV Humoral Memory Five Years After Cure in People with HIV: A Cross-Sectional Study.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: April 20, 2026
Plasma miRNA-Metabolite Dysregulation in People with HIV with Cirrhosis Despite Successful HCV Cure.
Plasma miRNA-Metabolite Dysregulation in People with HIV with Cirrhosis Despite Successful HCV Cure.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 15, 2025
HIV status defines distinct immunological drivers of persistent portal hypertension after HCV cure in people with advanced cirrhosis.
Journal: Frontiers in immunology
Published: August 10, 2025
Lipid and immune dysregulation and risk of metabolic disorders after HCV clearance in HIV/HCV-coinfected participants with cACLD: a retrospective study.
Journal: Frontiers in immunology
Published: July 28, 2025
Long-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis.
Journal: Journal of infection and public health
Published: April 28, 2025
Immune checkpoint proteins are associated with persistently high liver stiffness after successful HCV treatment in people with HIV: a retrospective study.
Journal: Frontiers in immunology
Published: October 03, 2024
Sustained Long-Term Decline in Anti-HCV Neutralizing Antibodies in HIV/HCV-Coinfected Patients Five Years after HCV Therapy: A Retrospective Study.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: August 01, 2024
Metabolomic Changes Associated With the Change in HVPG After DAAs Therapy in HCV Cirrhotic Patients.
Metabolomic Changes Associated With the Change in HVPG After DAAs Therapy in HCV Cirrhotic Patients.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: May 07, 2024
Altered blood microbiome in patients with HCV-related Child-Pugh class B cirrhosis.
Journal: Journal of infection and public health
Published: December 21, 2023
Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study.
Journal: Frontiers in pharmacology
Published: November 20, 2023
Last Updated: 09/26/2026